Table 2.
Characteristics of patients with positive versus negative Patient Health Questionnaire (PHQ)-2a scores
| PHQ-2 score ≥3 (N = 41b) n (%) |
PHQ-2 score <3 (N = 115b) n (%) |
P valuec | |
|---|---|---|---|
| Age at time of collection (mean ± SD, range) | 37.8 ± 15.1, 18–76 | 37.4 ± 14.5, 14–77 | .881 |
| Sex | >.999 | ||
| Male female | 9 (22.0) 32 (78.0) | 24 (20.9) 91 (79.1) | |
| Race | .171 | ||
| White | 9/38 (23.7) | 48/114 (42.1) | |
| Black | 12/38 (31.6) | 20/114 (17.5) | |
| Asian | 2/38 (5.3) | 8/114 (7.0) | |
| Multiracial | 1/38 (2.6) | 2/114 (1.8) | |
| Other | 14/38 (36.8) | 36/114 (31.6) | |
| Ethnicity | >.999 | ||
| Hispanic Non-Hispanic | 12/39 (30.8) 27/39 (69.2) | 32/105 (30.5) 73/105 (69.5) | |
| Smoking status | .833 | ||
| Never Current or Former | 32 (78.0) 9 (22.0) | 85/114 (74.6) 29/114 (25.4) | |
| Family history of HS | 12/32 (37.5) | 21/99 (21.2) | .099 |
| BMI classification | .078 | ||
| Underweight (<18.5) | 1/40 (2.5) | 1/112 (0.9) | |
| Normal weight (18.5–<25) | 4/40 (10.0) | 25/112 (22.3) | |
| Overweight (25–<30) | 7/40 (17.5) | 30/112 (26.8) | |
| Obese (30+) | 28/40 (70.0) | 56/112 (50.0) | |
| Anatomical regions involved | |||
| Face, Ears, and/or Neck | 6 (14.6) | 14 (12.2) | .786 |
| Chest/Inframammary | 9 (22.0) | 29 (25.2) | .833 |
| Axillae | 28 (68.3) | 62 (53.9) | .141 |
| Abdomen | 8 (19.5) | 11/113 (9.7) | .162 |
| Back | 2 (4.9) | 6/114 (5.3) | >.999 |
| Groin and/or Buttocks | 34 (82.9) | 90/112 (80.4) | .819 |
| Legs | 15/40 (37.5) | 40/112 (35.7) | .850 |
| Presence of sinus tracts/tunnels | 20/40 (50.0) | 49/113 (43.4) | .580 |
| Pain score (mean ± SD, range) | 5.1 ± 3.0, 0–10 | 2.7 ± 2.8, 0–10 | <.0001 |
| Itch score (mean ± SD, range) | 4.1 ± 3.5, 0–10 | 2.5 ± 2.8, 0–10 | .004 |
| Drainage | <.0001 | ||
| Any drainage No drainage | 34 (82.9) 7 (17.1) | 52/114 (45.6) 62/114 (54.4) | |
| Hurley stage | .612d | ||
| I | 5 (12.2) | 15/114 (13.2) | |
| II | 21 (51.2) | 63/114 (55.3) | |
| III | 15 (36.6) | 36/114 (31.6) | |
| HS-PGA | .037 | ||
| Clear (0) | 2/38 (5.3) | 21/108 (19.4) | |
| Minimal (1) | 3/38 (7.9) | 9/108 (8.3) | |
| Mild (2) | 17/38 (44.7) | 44/108 (40.7) | |
| Moderate (3) | 6/38 (15.8) | 25/108 (23.1) | |
| Severe (4) | 8/38 (21.1) | 7/108 (6.5) | |
| Very severe (5) | 2/38 (5.3) | 2/108 (1.9) | |
| DLQI (mean ± SD, range) | 17.8 ± 6.8, 2–30 | 8.3 ± 6.5, 0–28 | <.0001 |
| Returning patient at clinic | 18 (43.9) | 64 (55.7) | .208 |
| New patient at clinic | 23 (56.1) | 51 (44.3) | .208 |
| Biologic use at time of PHQ-2 visit | 11 (26.8) | 41 (35.7) | .340 |
BMI, body mass index; DLQI, Dermatology Life Quality Index; HS, hidradenitis suppurativa; HS-PGA, Hidradenitis Suppurativa Physician’s Global Assessment; PHQ-2, Patient Health Questionnaire-2; SD, standard deviation.
The PHQ-2 consists of two questions to assess for the frequency of depressed mood and anhedonia over the past 2 weeks: (1) little interest or pleasure in doing things and (2) feeling down, depressed, or hopeless. Each question is scored on a scale from 0 to 3, and a total score of 3 or higher is considered positive (range, 0–6).
Unless otherwise specified.
Fisher exact test was used for comparisons of categorical variables, and unpaired t tests were used for continuous variables, unless otherwise specified.
Cochran-Armitage Test for Trend utilized.